Ecospray Chooses relayr to Revolutionize the Maritime Industry With Artificial Intelligence Powered Solutions
Ecospray, a company specializing in the research and development of cutting-edge systems for controlling air and gas emissions in industrial applications for the Maritime industry, has chosen relayr, a leading industrial IoT company based in Berlin, to create new IoT-based desulphurization solutions, driving the sector towards an increasingly digital, efficient and environmentally sustainable future.
The Maritime Industry has been one of the latest in addressing the need to reduce its environmental impact. Now, with the introduction of IMO regulations aimed at reducing sulphur oxide emissions - which came into force in January 2020 - the industry is facing a rising pressure to comply with more stringent environmental regulations, as well as the need of containing costs and improve efficiency in an increasingly competitive and unpredictable market.
In this context, fleets can resort to various solutions, including the installation of scrubbers to remove SOx emissions, or using alternative fuels such as very-low-sulphur fuel oil (VLSFO) but with significantly higher costs compared to bunker fuel.
To meet these market challenges while aiming at developing new solutions capable of radically renewing the entire maritime transport sector, Ecospray has chosen to collaborate with relayr , a company specializing in IoT solutions oriented for business outcomes. The partnership between the two companies will allow the creation of a new generation of emission control equipment: smart scrubbers managed using artificial intelligence, a completely new solution for the market.
Ecospray, market leader in marine emission purification systems (EGCS), has always been committed to developing technological solutions for the maritime sector that can make the processes of reducing the pollutants in the gases produced by ships more efficient. The integrated technologies offered by Ecospray aim at reducing emissions and saving fuel, leading ship owners on the path towards decarbonization of the sector and encouraging the use of clean energy. Part of Carnival Group since 2013, the Italian company has continued to grow in recent years by increasingly specializing in offerings for the marine segment.
"Being part of Carnival Corporation has given us the opportunity to implement high-performance and reliable technological solutions in record time. We were enabled to gain experience across the entire fleet and unparalleled sailing experience, which has allowed us to build robust and use case specific innovations at speed," said Stefano Di Santo, CEO of Ecospray.
The new IMO-compliant devices are not only an innovation that drives an environmentally intensive industry towards a more sustainable future but also an investment that will significantly reduce equipment-running costs for shipbuilders.
The integration of relayr’s IIoT and AI offering tailored to the devices allows to guarantee constant compliance with IMO regulations for the containment of air pollution in the maritime environment. Moreover, it allows significant savings in terms of performance and maintenance through remote monitoring and advanced life cycle analysis. The ability to constantly monitor and analyze the scrubbers’ performance ensures longer equipment life and fuel savings by optimizing pumping operations while also allowing a significant reduction in operating costs.
"We are delighted to collaborate with a company like Ecospray, igniting together the digital transformation of the marine industry," says Josef Brunner, CEO of relayr. "This partnership allows us to enter a new market – bringing high added value with IIoT solutions, helping to exploit the full potential of the control systems machines, and ultimately contributing to the reduction of harmful gas emissions."
“In the maritime industry, a fleet could include hundreds of ships, so the opportunities to build smart machines on such a large scale are literally endless," commented Stefano Di Santo, CEO of Ecospray. "The partnership with relayr allows us to confidently face the challenge of bringing the best of 4.0 technologies to the naval sector. The constant motivation that this project offers us on a daily basis requires a totally different and creative approach to problem solving. I am certain of one thing: together we will never stop improving. Ecospray and relayr: disrupting innovations across the oceans."
The process of digitalization of equipment for gas emission control is only a first step towards a broader business transformation process for the Alessandria-based Ecospray. The visionary approach in collaboration with relayr ultimately envisages the adoption of the Equipment as a Service (EaaS) model. Unlike the traditional asset purchase model, EaaS is based on a pay-per-use offering, in which equipment is no longer purchased but provided in exchange for a usage fee.
Thanks to relayr's experience in implementing the EaaS model, Ecospray will be able to create even more value for its customers, diversifying its revenue streams by offering new services and emerging in the current market scenario.
About Ecospray
From research to development, Ecospray Technologies is specialized in integrated solutions for the green conversion of the maritime and land industries as well as the reduction of dependency on fossil fuels. Founded in 2005 and part of Carnival Group since 2013, Ecospray operates at global level, offering systems aimed at making industrial processes more sustainable through the purification and treatment of pollutants, from emission removal to fuel saving and water filtration. Ecospray's technological solutions leverage three distinctive factors – technology delivered as a service, analysis and use of relevant data, and finance – to facilitate access to innovation and significantly advance the energy transition towards decarbonization and the creation of clean energy.
About relayr
Relayr is the Industrial Internet of Things (IIoT) powerhouse delivering the most complete solutions for risk-free digital transformations. We unleash data insights from existing equipment, machines and production lines to improve our customers’ business outcomes. We enable industrial companies to shift from CAPEX to OPEX-based offerings on their respective markets, providing a unique combination of first-class IIoT technology and its delivery with powerful financial and insurance offerings – all from a single source trusted by hundreds of companies worldwide. With relayr, manufacturers, operators, and service companies for industrial equipment are empowered to implement fully interoperable IIoT solutions guaranteed to achieve their target business outcomes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005584/en/
Contact information
Ecospray
Eleonora Castiglione
Marketing & Communications Manager
castiglione@ecospray.eu
relayr
David Petrikat
Senior Vice President Marketing & Portfolio
david.petrikat@relayr.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom